Vmbook Online ordering

Ibio Inc

iBio, Inc. (IBIO) is a USA-based biotechnology company that specializes in the development and production of biotherapeutics and vaccines using its proprietary platform, known as the FastPharming System. The company is focused on addressing unmet medical needs in the areas of infectious diseases, cancer, and fibrosis.

Here's a summary of some key information on iBio, Inc.:

Stock Exchange Listing: The company's common stock is listed and traded on the NASDAQ Stock Market LLC under the ticker symbol "IBIO."

Market Capitalization: As of March 15, 2023, iBio's market capitalization is approximately $83.92 million.

Earnings: iBio, Inc. has not reported any net income in the last three years, with net losses in 2021 and 2020 being $39.1 million and $50.2 million, respectively.

Revenue: iBio's revenue has been decreasing since 2019, with 2021 revenues at $1.17 million, down from $4.47 million in 2019.

Cash Position: iBio had cash and cash equivalents of $6.54 million in Q3 2022, with no debt and total liabilities of approximately $13.4 million.

Pipeline: iBio's product pipeline includes:

1. IBIO-200 (Phase 1) - a COVID-19 vaccine candidate based on its SARS-CoV-2 spike protein

2. IBIO-201 (Preclinical) - a universal influenza vaccine candidate that targets multiple strains

3. IBIO-100 (Phase 1) - a therapeutic candidate targeting idiopathic pulmonary fibrosis and other fibrotic diseases

Partnerships: iBio has entered into collaborations with prominent organizations like the Texas A&M University System, Califormula Biotherapeutics and CC-Pharming, to develop and produce vaccine and therapeutic candidates.

Analyst Ratings: As of March 15, 2023, there are no active ratings on iBio, Inc. from Wall Street analysts.

In summary, iBio, Inc. is a loss-making biotechnology company with a focus on infectious diseases, cancer, and fibrosis. Its valuation remains modest as it commercially develops its product pipeline in partnership with several organizations and is rapidly advancing towards the next stages of clinical trials for its candidates.